AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteBMS-708163 is an oral gamma secretase inhibitor designed for selective inhibition of amyloid beta synthesis.
More Information Supplier PageBMS-708163 is an oral gamma secretase inhibitor designed for selective inhibition of amyloid beta synthesis.
More Information Supplier PageBMS-708163 is an oral gamma secretase inhibitor designed for selective inhibition of amyloid beta synthesis.
More Information Supplier PageBMS-708163 is an oral gamma secretase inhibitor designed for selective inhibition of amyloid beta synthesis.
More Information Supplier PageBMS-740808 is a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
More Information Supplier PageBMS-740808 is a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
More Information Supplier PageBMS-740808 is a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
More Information Supplier PageBMS-740808 is a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
More Information Supplier PageBMS-747158-02 is a fluorine 18?Clabeled pyridaben derivative designed as a new myocardial perfusion imaging agent for use with positron emission tomography (PET).
More Information Supplier PageBMS-747158-02 is a fluorine 18?Clabeled pyridaben derivative designed as a new myocardial perfusion imaging agent for use with positron emission tomography (PET).
More Information Supplier PageBMS-747158-02 is a fluorine 18?Clabeled pyridaben derivative designed as a new myocardial perfusion imaging agent for use with positron emission tomography (PET).
More Information Supplier PageBMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family-targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents.
More Information Supplier PageBMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family-targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents.
More Information Supplier PageBMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family-targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents.
More Information Supplier PageBMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family-targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents.
More Information Supplier PageBMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family-targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents.
More Information Supplier PageBMS-777607 is a MET tyrosine kinase inhibitor that binds to c-Met protein, or HGFR, preventing binding of HGF and disrupting the MET signaling pathway.
More Information Supplier PageBMS-777607 is a MET tyrosine kinase inhibitor that binds to c-Met protein, or HGFR, preventing binding of HGF and disrupting the MET signaling pathway.
More Information Supplier PageBMS-777607 is a MET tyrosine kinase inhibitor that binds to c-Met protein, or HGFR, preventing binding of HGF and disrupting the MET signaling pathway.
More Information Supplier PageBMS-777607 is a MET tyrosine kinase inhibitor that binds to c-Met protein, or HGFR, preventing binding of HGF and disrupting the MET signaling pathway.
More Information Supplier PageBMS-790052 is an NS5A inhibitor under investigation for the treatment of hepatitis C virus (HCV) infection.
More Information Supplier PageBMS-790052 is an NS5A inhibitor under investigation for the treatment of hepatitis C virus (HCV) infection.
More Information Supplier PageBMS-790052 is an NS5A inhibitor under investigation for the treatment of hepatitis C virus (HCV) infection.
More Information Supplier PageBMS-790052 is an NS5A inhibitor under investigation for the treatment of hepatitis C virus (HCV) infection.
More Information Supplier PageBMS-790052 is an NS5A inhibitor under investigation for the treatment of hepatitis C virus (HCV) infection.
More Information Supplier PageBMS-790052 is an NS5A inhibitor under investigation for the treatment of hepatitis C virus (HCV) infection.
More Information Supplier PageBMS-790052 is an NS5A inhibitor under investigation for the treatment of hepatitis C virus (HCV) infection.
More Information Supplier PageBMS-790052 is an NS5A inhibitor under investigation for the treatment of hepatitis C virus (HCV) infection.
More Information Supplier PageBMS-790052 is an NS5A inhibitor under investigation for the treatment of hepatitis C virus (HCV) infection.
More Information Supplier PageBMS-794833 is a potent ATP competitive inhibitor to Met and VEGFR-2 with IC50 of 1.7 and 15 nmol.
More Information Supplier PageBMS-794833 is a potent ATP competitive inhibitor to Met and VEGFR-2 with IC50 of 1.7 and 15 nmol.
More Information Supplier PageBMS-794833 is a potent ATP competitive inhibitor to Met and VEGFR-2 with IC50 of 1.7 and 15 nmol.
More Information Supplier PageBMS-794833 is a potent ATP competitive inhibitor to Met and VEGFR-2 with IC50 of 1.7 and 15 nmol.
More Information Supplier PageBMS-794833 is a potent ATP competitive inhibitor to Met and VEGFR-2 with IC50 of 1.7 and 15 nmol.
More Information Supplier PageBMS-806, also known as BMS-378806 , is a type of medicine called an entry inhibitor. Entry inhibitors work by blocking HIV from entering human cells. BMS-378806 (BMS-806) is a small molecule that blocks the binding of host-cell CD4 with viral gp120 protein and therefore inhibits the first steps of HIV-1 infection.
More Information Supplier PageBMS-806, also known as BMS-378806 , is a type of medicine called an entry inhibitor. Entry inhibitors work by blocking HIV from entering human cells. BMS-378806 (BMS-806) is a small molecule that blocks the binding of host-cell CD4 with viral gp120 protein and therefore inhibits the first steps of HIV-1 infection.
More Information Supplier PageBMS-806, also known as BMS-378806 , is a type of medicine called an entry inhibitor. Entry inhibitors work by blocking HIV from entering human cells. BMS-378806 (BMS-806) is a small molecule that blocks the binding of host-cell CD4 with viral gp120 protein and therefore inhibits the first steps of HIV-1 infection.
More Information Supplier PageBMS-806, also known as BMS-378806 , is a type of medicine called an entry inhibitor. Entry inhibitors work by blocking HIV from entering human cells. BMS-378806 (BMS-806) is a small molecule that blocks the binding of host-cell CD4 with viral gp120 protein and therefore inhibits the first steps of HIV-1 infection.
More Information Supplier PageBMS-806, also known as BMS-378806 , is a type of medicine called an entry inhibitor. Entry inhibitors work by blocking HIV from entering human cells. BMS-378806 (BMS-806) is a small molecule that blocks the binding of host-cell CD4 with viral gp120 protein and therefore inhibits the first steps of HIV-1 infection.
More Information Supplier PageBMS-817378 is a novel prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833.
More Information Supplier PageBMS-817378 is a novel prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833.
More Information Supplier PageBMS-817378 is a novel prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833.
More Information Supplier PageBMS-833923 (or XL-139) is an orally bioavailable small-molecule SMO (Smoothened) inhibitor with potential antineoplastic activity.
More Information Supplier PageBMS-833923 (or XL-139) is an orally bioavailable small-molecule SMO (Smoothened) inhibitor with potential antineoplastic activity.
More Information Supplier PageBMS-833923 (or XL-139) is an orally bioavailable small-molecule SMO (Smoothened) inhibitor with potential antineoplastic activity.
More Information Supplier PageBMS-833923 (or XL-139) is an orally bioavailable small-molecule SMO (Smoothened) inhibitor with potential antineoplastic activity.
More Information Supplier PageBMS-833923 (or XL-139) is an orally bioavailable small-molecule SMO (Smoothened) inhibitor with potential antineoplastic activity.
More Information Supplier PageBMS-863233, also known as XL-413, is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity.
More Information Supplier PageBMS-863233, also known as XL-413, is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity.
More Information Supplier PageBMS-863233, also known as XL-413, is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity.
More Information Supplier Page
